Type-I IFN-dependent control of HSCs and its therapeutic applications for congenital and hematopoietic disorders

我们发现瞬时I型IFN信号诱导HSC激活，而慢性I型IFN信号进一步减少静止HSC的数量。基于我们的研究结果，我们建立了基于I型ifn的无辐照HSC移植预处理方案，该方案适用于先天性代谢性疾病粘多糖病VII型的治疗。此外，用伊马替尼和poly(I: C)（一种I型IFN诱导剂）治疗慢性髓性白血病（CML），可显著降低疾病的复发率。

We found that transient type I IFN signaling induced HSC activation and chronic type I IFN signaling further reduced the number of quiescent HSCs. Based on our findings, we established type I IFN-based preconditioning regimen without irradiation for HSC transplantation, which is applicable to the treatment of a congenital metabolic disorder, mucopolysaccharidosis type VII. In addition, the treatment of chronic myeroid leukemia(CML) with imatinib and poly(I : C), a type I IFN inducer, significantly reduced the recurrence rate of the disease.